NEW YORK (GenomeWeb) – German molecular diagnostics firm New Oncology today announced a collaboration to help the National Cancer Centre Singapore offer personalized cancer treatment using the company's proprietary diagnostic platform, Neo.
Neo enables physicians to optimize treatment for their patients by providing a tumor profile showing all types of therapeutically relevant genetic alterations, including mutations, amplifications, insertions and deletions, as well as novel and known translocations, the firm said in a statement.
Andreas Jenne, CEO of New Oncology, said that the deal is a major milestone in the firm's international business expansion. Financial and other details of the agreement were not disclosed.
New Oncology, the molecular diagnostics division of genomic analytics firm Blackfield, is based in Cologne, Germany. Its NeoPlus pan-cancer diagnostic test reliably detects genetic alterations from a single patient sample with short turn-around times.